Karyopharm Therapeutics Inc. reiterated revenue guidance for the full year 2023. For the year, the company expected total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | 0.00% | -9.40% | +22.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.54% | 123M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023